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ABSTRACT 
Objective: The objective of the present study was to develop, and validate a novel reverse phase high performance liquid chromatographic (RP-
HPLC) method, for simultaneous determination of saxagliptin (SAXA) and glimepiride (GLIM), in bulk mixtures, and in tablets. 
Methods: Determination of the drugs, SAXA and GLIM, was carried out employing ODS C18 column (250 mm X 4.6 mm i. d, 5 µm particle size), with 
diode array detector at λmax of 230 nm. The mobile phase employed for the current study, composed of two solvents, i.e., A (acetonitrile), and B (0.1 
% w/v sodium di-hydrogen orthophosphate buffer, pH 3.8 adjusted with orthophosphoric acid). The mobile phase was pumped at a flow rate of 
0.75 ml/min in the gradient mode. The validation study with respect to specificity, linearity, precision, accuracy, robustness, limit of detection 
(LOD), and limit of quantification (LOQ), was carried out employing the ICH Guidelines. 
Results: The developed method was selective and linear for both the drugs, i.e., between 15.63 µg/ml and 250.00 µg/ml for SAXA, and 7.81 µg/ml 
and 125.00 µg/ml for GLIM, with a correlation coefficient (R2) 0.9977 and 0.9982, for SAXA, and GLIM, respectively. The % recovery obtained was 
102.98±0.14% for SAXA, and 101.84±1.96% for GLIM. The LOD and LOQ values for SAXA were obtained to be 1.30 µg/ml, and 3.94 µg/ml, 
respectively, while for GLIM, LOD was 0.82 µg/ml and LOQ was 2.48 µg/ml. The method also exhibits good robustness for different 
chromatographic conditions like wavelength, flow rate, mobile phase and injection volume. 
Conclusion: The method was successfully employed, for the quantification of SAXA and GLIM, in the quality control of in-house developed tablets, 
and can be applied for the industrial use. 
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Saxagliptin (SAXA), (1S, 3S, 5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo 
[3.3.1.13, 7] dec-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile, 
a novel oral hypoglycaemic drug of the dipeptidyl peptidase-4 (DPP-4) 
inhibitor class, has initiated a new therapeutic approach for the 
treatment of type 2 diabetes (T2D) mellitus. Structurally, SAXA (fig. 1A) 
is a cyanopyrrolidine derivative, which is designed to provide extended 
inhibition of DPP-4 enzyme [1]. DPP-4 inhibitors like SAXA, not only 
inhibit the degradation, but also increase the circulating levels of intact 
and active glucagon-like peptide-1 (GLP-1), and glucose-dependent 
insulinotropic polypeptide (GIP). GLP-1 has multiple important 
glucoregulatory effects, including promotion of glucose-dependent 





























Fig. 1: Structure of, (A): Saxagliptin; (B): Glimepiride 
 
Glimepiride (GLIM) (1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-
1-carboxamido) ethyl] phenyl] sulfonyl]-3-(trans-4-methyl-
cyclohexyl) urea) (fig. 1B), a first third-generation sulphonylurea 
agent, is a commonly accepted drug in the treatment of T2D [3, 4]. It 
acts by stimulating insulin secretions from the beta cells of the 
pancreas and is also known to increase peripheral insulin sensitivity, 
thus decreasing insulin resistance. 
Hypoglycaemia is a major concern, when there is a chronic 
administration of antidiabetic drugs in the management of T2D. 
However, SAXA exhibited a low risk of hypoglycaemia in comparison 
to other antidiabetic drugs when was used either as a monotherapy 
or in combination [5-11]. There was no hypoglycemic effect 
observed when sulphonylureas like GLIM, or Glyburide, was used in 
combination therapy with SAXA, which could have otherwise 
appeared if the either drug would have been used alone [12]. 
Currently, SAXA in combination with sulfonylurea is undergoing 
clinical trials according to Therapeutic Goods Administration (TGA) 
guidelines [13]. Both DPP-4 inhibitors and sulphonylureas increase 
insulin secretion, produce a synergistic effect, and thus suggest their 
utility in combination therapy [14]. In comparison to the mono-
therapy of drugs, i.e., either GLIM or SAXA, their simultaneous 
prescription can lead to same clinical effect at very low doses 
without eliciting the hypoglycaemia. 
Hitherto, different analytical methods are reported, for the 
determination of SAXA and GLIM individually, or in combination 
with other drugs, in the pharmaceutical formulations. The methods 
are ultraviolet (UV) [15-20], reverse phase high-performance liquid 
chromatography (RP-HPLC) [21-31], and liquid chromatographic 
mass spectroscopy (LCMS) [32, 33], for the determination of the 
SAXA and GLIM individually, or in combination with metformin, 
pioglitazone, and atorvastatin. However, no reports are traceable in 
the literature for the simultaneous estimation of SAXA and GLIM. 
Therefore, there is a need to develop and validate an analytical 
method, which could simultaneously determine the drugs in 
pharmaceutical formulations for quality control purposes. 
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MATERIALS AND METHODS  
Instrumentation 
The chromatographic system used to develop the current technique 
is an Agilent Technologies 1200 series, Waldbronn, Germany, 
featuring a binary pump system (G1312A), an automatic injector 
(G1329A), and a diode array detector (DAD) (G1315D), which was 
set at 230 nm. Data acquisition was performed using a 
chromatography software package (EZChrome). 
Chemicals and reagents 
The drug SAXA and GLIM were procured from Raks Pharma Pvt. Ltd. 
Viskhapatnam, A. P., India. All other chemicals and solvents, like 
acetonitrile, sodium dihydrogen orthophosphate, orthophosphoric 
acid, and water, employed for the study were HPLC grade, supplied 
by Loba Chemie Pvt. Ltd, Mumbai, India. Pharmaceutical excipients 
for preparation were: microcrystalline cellulose pH 101, corn-starch, 
lactose monohydrate, magnesium stearate and talc obtained from 
Loba Chemie Pvt. Ltd, Mumbai, India. A placebo for the validation 
study was prepared with these excipients. 
Chromatographic conditions 
Chromatographic separation of the active drugs, i.e. SAXA and GLIM 
was performed using an Innoval C18 column (5 µm, 4.6 mm i. d × 
250 mm) made of stainless steel. Two different mobile phases for 
pumps were: mobile phase A: acetonitrile (ACN)) and mobile phase 
B: buffer. As, isocratic flow was not suitable for simultaneous 
estimation of SAXA and GLIM, hence gradient flow of mobile phases, 
at a flow rate of 0.75 ml/min from two different pumps was followed 
and found to be most suitable. The gradient flow of solvents A and B, 
comprised of total time period of 30 min, and was in the following 
order: A: B::30:70 for 0-2 min, A: B: :50:50 for 2-25 min, and A: B: 
:30:70 for 25-30 min. The composition of buffer was 0.1 % sodium 
di-hydrogen ortho-phosphate, pH 3.8 adjusted with orthophosphoric 
acid. Both, the ACN and the buffer solution were filtered through a 
0.45 µm nylon-membrane filter, and ultra-sonicated for 15-20 min. 
Samples were filtered through the syringe filter of 0.22 μm pore size, 
prior to the injection. The injection volume of sample to carry out 
the chromatography was fixed as 10 µl. The column temperature 
was maintained at 30 °C. 
Stock and working solutions 
Separate standard solutions of SAXA and GLIM, were prepared at a 
concentration of 500 µg/ml, and 250 µg/ml respectively, dissolving 
the appropriated amount of bulk material in ACN. By adding an 
equal ratio of SAXA and GLIM solutions, a simultaneous stock 
solution was prepared, wherein the final concentrations of SAXA and 
GLIM, were 250 µg/ml, and 125 µg/ml, respectively. Further five 
levels in the range of, 15.63-250 µg/ml for SAXA and 7.81-125 µg/ml 
for GLIM, were prepared by diluting the stock solutions 
appropriately with ACN. All drug samples were protected from the 
light by employing amber coloured glass vials. 
Validation study 
Specificity 
For the specificity study, identification of the active drugs, i.e., SAXA 
and GLIM was studied individually, and simultaneously, by 
comparing the raw material (mobile phase+SAXA, mobile 
phase+GLIM and mobile phase+SAXA+GLIM) with a standard of 
their respective references (mobile phase+SAXA CRS, mobile 
phase+GLIM CRS, and mobile phase+SAXA CRS+GLIM CRS).  
Another study carried out was to check the absence of any 
interference, by the excipients that were employed, in the 
formulation of the tablet form SAXA and GLIM.  
Linearity and range 
The linearity of the method, used for the analysis of SAXA and GLIM, 
was evaluated from the standard curve plotted between peak area 
and analyte concentration. Calibration curves taking five points in 
each case were generated on the three consecutive days with 
standard working solutions. The concentration ranges were 15.63-
250.00 µg/ml for SAXA, and 7.81-125.00 µg/ml for GLIM. Range is 
defined as the interval between the minimum and maximum 
concentration which is analysed by the given chromatographic 
conditions within permissible limit of precision and accuracy. Least 
square linear regression analysis was applied on the obtained 
chromatographic data employing MS-Excel 2013 spreadsheet 
software and carrying out the corresponding statistic study. 
Precision 
For the precision study, instrumental precision, and inter-day, and 
intraday precision studies, were carried out. The first one consisted 
of checking the instrumental precision, where a sample 
corresponding to a concentration within the linearity range, injected 
6 times, consecutively into the chromatograph, repeating the 
operation on the second day. Interday and intraday, precision were 
determined by analyzing three concentrations, selected from 
linearity range, i.e., 31.25, 62.5, and 125.00 µg/ml for SAXA, and 
15.63, 31.25 and 62.50 µg/ml for GLIM. Three replicate of each 
concentration were analyzed on 1st and 2ndday for interday 
precision. Similarly, the same set of concentrations were also 
analyzed in triplicate at different intervals within a day for intraday 
precision. The peak area was determined, and the precision was 
reported as % relative standard deviation (RSD).  
Accuracy (recovery method) 
The accuracy of the method was also studied, at three final 
concentration levels, i.e., 31.25, 62.50, and 93.75 µg/ml for SAXA, 
and 15.63, 31.25, and 46.88 µg/ml for GLIM. In this method, a known 
amount of the active was added to a determined amount of placebo 
and was subsequently calculated for SAXA and GLIM, recovered in 
relation to the added amount of the drugs.  
Robustness 
The study of robustness was carried out to evaluate the influence of 
small, but deliberate variations, in the chromatographic conditions, 
for the determination of SAXA, and GLIM, in tablets. The 
chromatographic factors, chosen for this study, were the wavelength 
(nm), flow rate (ml/min), mobile phase (% ACN), and volume of 
injection (2 µl). The peak area was determined, and the robustness 
was reported as % RSD. 
Limit of detection (LOD) and limit of quantification (LOQ)  
LOD, is the smallest concentration, which the analytical method, on a 
given instrument and chromatographic conditions, is able to 
differentiate the compound from the background noise, While, the 
LOQ, is the smallest concentration which is quantifiable with defined 
precision and accuracy. To determine LOD, and LOQ separately for 
SAXA, and GLIM, a sample containing selected minimum 
concentration for each drug, was injected repeatedly, and analysed 
to calculate the standard deviation. Finally, LOD and LOQ were 
calculated as per the equations 1 and 2, according to the ICH 
guidelines, wherein, “s” is the slope of the curve(s), and standard 
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Preparation of tablets 
Wet granulation method was used to prepare the tablet formulation 
containing the active drugs [34]. The active drugs and excipients 
were passed through different mesh screens. SAXA, GLIM, 
microcrystalline cellulose (MCC), lactose monohydrate, and starch, 
were passed through 30 mesh, while magnesium stearate and talc, 
were pass through 60 mesh screen. A 10 % w/v aqueous solution of 
starch was employed as a binder. Drugs (SAXA and GLIM), MCC, and 
lactose monohydrate were mixed thoroughly in required amount, 
and sufficient volume of 10 % starch solution was added to obtain a 
damp mass. Afterwards, the mass was sieved through 20 mesh 
screen to obtain granules, and were subsequently dried at 60 °C for 
1 h. Finally, magnesium stearate and talc were added to the granules, 
and mixed thoroughly. Lastly, the tablets were compressed by using 
eight station tablet punching machine 
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Dissolution study 
The in vitro dissolution study of tablet formulation was determined 
by using USP Type 2 (paddle type) eight station dissolution 
apparatus (Eletrolab dissolution apparatus). The dissolution media 
used was composed of phosphate buffer pH 6.8 USP, and 0.1N HCl 
USP. The test was performed for 6 tablets in 900 ml of 0.1N HCl, and 
pH 6.8 buffer, at 50 rpm maintained at 37±0.5 °C. The 5 ml volume of 
samples was withdrawn at predetermined time intervals, for the 
period of 2 h (0, 5, 15, 30, 45, 60, 75, 90, 120 min), and replaced with 
the equal volume of the same dissolution medium. The samples were 
filtered through 0.2 μm nylon membrane syringe filter. Amount of 
SAXA and GLIM released from the tablets at each time point, was 
analyzed by developed RP-HPLC method [35-37]. 
RESULTS AND DISCUSSION 
System suitability 
The chromatographic separation of SAXA and GLIM, as explained 
earlier, was carried out employing an Innoval C18 column (5 µm, 4.6 
mm × 250 mm). The chromatographic parameters namely, number 
of theoretical plates, retention time, an asymmetric factor of the 
peaks, and HETP, were evaluated and are included in the table 1. The 
number of theoretical plates for SAXA, was 4659, while for GLIM, it 
was 21889. The values for asymmetric of peaks were 1.33 and 1.67 
for SAXA, and GLIM, respectively. Further, the tailing factor values 
were obtained to be 1.14 for SAXA, and 1.07 for GLIM.  
Fig. 2 revealed that there was no interference in the chromatograms 
of SAXA and GLIM, with any of the peaks of placebo. None of the 
peaks of excipients observed at the same retention time of SAXA and 
GLIM. The resolution obtained between SAXA and GLIM was quite 
good, i.e., 3.28 min for SAXA and 26.13 min for GLIM. 
It was concluded that the developed method is optimum according 
to the studied chromatographic parameters. The values of the 
number of theoretical plates were higher than the accepted value of 
2000 according to ICH [38]. The tailing factor and asymmetry the 
peak, both the factors were well within the limits (table 1) and 
revealed quite a good separation. Therefore, this method can be 
applied in routine to analyse without any difficulty. 
Validation study 
Specificity 
The purity of the chromatographic peaks studied for SAXA and GLIM at 
different time points were well within the established threshold values.  
It was observed in chromatogram that the excipients interference 
for pharmaceutical preparation was showing none of the peaks at 
the same retention time of both drugs (fig. 3). 
Hence, it can be stated that none of the peaks generated by the 
excipients treatment interfere with the peaks corresponding to the 
active ingredients, therefore showing it to be a selective method and 
suitable for routine analysis. 
Linearity 
The equation of the regression curve obtained relating the tested 
concentrations (table 2) and the response obtained correspond to y 
= 19935x+40611, and y = 155343x+408956 for SAXA and GLIM, 
respectively. The correlation coefficient for SAXA was obtained to be 
0.9977 and for GLIM 0.9982.  
Excellent linearity was obtained for both the drugs in the range of 
15.63-250.00 µg/ml for SAXA and 7.81-125.00 µg/ml for GLIM. The 
correlation coefficients for both drugs were found to be higher than 
the critical value of 0.995 (fig. 4 and table 1). 
 
 
Fig. 2: Chromatogram of, (A): Placebo chromatogram; (B): Overlay chromatogram of a calibration curve for SAXA and GLIM 
 
Table 1: Chromatographic characteristics of the RP-HPLC method 
Parameter SAXA GLIM Acceptance  
Conc. Range (µg/ml) 15.63-250.00 7.81-125.00 Non 
LOD (µg/ml) 1.30 0.82 
LOQ (µg/ml) 3.94 2.48 
Regression equation y = 19935x+40611  y = 155343x+408956  
Correlation Coefficient 0.9977 0.9982 0.995≤ R² 
Accuracy (%Mean Recovery) 102.98±0.14 101.84±1.96 97-103% 
Precision Interday Day 1 1.225±0.695 0.797±0.443 %RSD≤2 
Day 2 0.920±0.815 0.873±0.517 
Precision Intraday Morning 1.225±0.695 0.797±0.443 
Evening 1.208±0.680 0.797±0.444 
Retention time 3.28 min 26.12 min Non 
Tailing factor 1.17 1.07 %RSD≤2 
Asymmetry of peak 1.33 1.14 %RSD≤2 
Theoretical plates 4659 21889 ˃2000 
HETP 1.50 µm 0.03 µm ≤100 µm 
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Fig. 3: Overlay of SAXA, GLIM, Blank, SAXA+GLIM, and their corresponding CRS 
 
Table 2: Linearity range with area 
S. No. SAXA GLIM 
Concentration (µg/ml) Area (mean±SD*) (mAU) Concentration (µg/ml) Area(mean±SD*) (mAU) 
1 15.63 487570±5157 7.81 2058898±32741 
2 31.25 606590±7596 15.63 2487638±26552 
3 62.50 1239162±6413 31.25 5289563±54861 
4 125.00 2449142±46685 62.50 9870512±28140 
5 250.00 5076379±29842 125.00 19960252±100936 
*SD = Standard Deviation, (n=3) 
 
 
Fig. 4: Calibration graph of, (A): GLIM; (B): SAXA (Results are expressed as mean±SD, n=3) 
 
Precision 
To study the precision for the instrumental system an interday study 
(n=6 samples for a day) was carried out. The % RSD values were 
obtained separately for RT and area for both the drugs at different time 
points (i.e. days). The % RSD values for RT and areas were 0.55 and 0.63, 
respectively for SAXA however, for GLIM it was 0.93 and 0.73. According 
to ICH the % RSD values should be less than 2 % for the precision study 
of the HPLC instrumental system [14], thus it can be concluded that the 
instrument used for the current study worked correctly for the 
developed analytical RP-HPLC method, and has been highly repetitive.  
For the interday and intraday precision studies, the selected 
concentration for SAXA were 31.25, 62.50 and 125.00 µg/ml, while for 
GLIM, it was 15.63, 31.25 and 62.50 µg/ml. All the concentrations for 
both the drugs, at different time points were analysed in triplicate (n=3). 
The % RSD values obtained for the first day were 1.225 for SAXA, and 
0.797 for GLIM. Similarly, same set of concentrations were also analyzed 
in triplicate at different times, within a day, for intraday precision. The % 
RSD values obtained for SAXA was 1.208, and for GLIM, it was 0.797. For 
the interday study, the three set of concentrations of same analyte were 
analyzed at different days, and % RSD values were obtained to be 0.919 
and 0.873 for SAXA, and GLIM respectively. As all the values for % RSD is 
less than 2 %, hence, the developed method is confirmed to be precise 
according to ICH [14]. 
Accuracy (recovery method)  
For the accuracy study from the 9 samples, i.e. n=3 for 50 %, n=3 for 
100 % and n=3 for 150 %. The results indicated that the mean of 
recovery for SAXA was 102.98 %, and % RSD was 0.131, similarly, 
mean of recovery for GLIM was 101.84 %, and % RSD was 1.924. As 
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both % RSD values are less than 2 % [14], hence, the reported % 
recovery by the developed method of the known added amount of 
analyte in the sample was within the confidence intervals.  
Robustness 
To evaluate the influence of small variations in the chromatographic 
conditions, robustness was evaluated, for different chromatographic 
conditions like wavelength, flow rate, mobile phase and injection 
volume. The studied wavelength was 230±5 nm, while flow rate was 
varied from 0.70 ml/min to 0.80 ml/min. The mobile phase ratio 
was also varied, i.e.,±5 % from the initial values. Further injection 
volume was kept as 5±1 µl. In all the cases, % RSD values obtained 
were less than 2 %, indicating that the developed method was 
consistent with respect to all the studied chromatographic 
conditions [39-40]. 
LOD and LOQ 
LOD and LOQ were determined for SAXA, and GLIM, as per the ICH 
guidelines, using the equations 1 and 2, wherein, ‘σ’ was the 
standard deviation (SD) of the response, and ‘S’ was the slope of 
calibration curve. The LOD value obtained for SAXA, was 1.30 µg/ml, 
while for GLIM, it was 0.82 µg/ml. Similarly, LOQ obtained for SAXA, 
was 3.94 µg/ml, and 2.48 µg/ml, for GLIM.  
Preparation of tablets 
The tablets were prepared by the wet granulation technique as 
described in the methods. Average weight of tablets was 105±5 mg. 
Each tablet contained 10 mg of SAXA and 5 mg of GLIM along with 
the other pharmaceutical ingredients as per the composition is given 
in table 3. 
 
Table 3: Composition of the tablet 
S. No. Ingredients  Per tablet (mg) 
1 SAXA 10 
2 GLIM 5 
3 MCC 50 
4 Lactose monohydrate 20 
5 Corn-starch  15 
6 Magnesium stearate  2.5 
7 Talc  2.5 
Total  105 
 
Dissolution study 
It is clearly vivid from the graph fig. 5, that there was a continuous 
increase in the % CDR values of both the drugs, i.e., SAXA and GLIM 
up to 90 min, in phosphate buffer pH 6.8. The maximum % CDR 




Fig. 5: Dissolution profiles of SAXA and GLIM tablet in, (A): pH 6.8; (B): 0.1N HCl (All the values were calculated as mean±SD, n=6) 
 
In 0.1N HCL both the drugs showed up quite a good release up to 90 
min. The % CDR was 97 % for SAXA and 96.68 % for GLIM, which is 
indicating the complete drug release in 0.1N HCl.  
CONCLUSION 
A simple and new RP-HPLC analytical method has been developed 
for the simultaneous estimation of SAXA and GLIM for routine 
analysis in bulk drug mixtures and tablets. The proposed method to 
determine SAXA and GLIM in tablets has been validated in terms of 
linearity, precision, accuracy, and selectivity, according to Q2B ICH 
guidelines and can be applied in routine and in quality control of 
SAXA and GLIM tablets. It has been proved that the developed 
method was selective, linear for both the drugs between 50 and 150 
% of the work concentration, and between quantification limit, and 
150 % for the both of drugs for tablets with a correlation coefficient 
(R2) higher than 0.995. It is also showing good robustness for 
different chromatographic conditions like wavelength, flow rate, 
mobile phase and injection volume. The method is convenient 
because of well-defined chromatographic conditions which can be 
used for routine analysis in the industrial set-up.  
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